MyFinsight
Home
Blog
About
Contact
Download
Download image
Cash and cash
equivalents
$457,607K
Marketable securities,
current
$178,498K
Prepayments and other
receivables
$20,603K
Restricted cash
$1,336K
Total current assets
$658,044K
Marketable securities, net
of current portion
$71,239K
Long term prepaid
expenses
$2,585K
Property, plant and
equipment, net
$379K
Intangible assets
$375K
Operating right of use
asset
$21K
Total assets
$732,643K
Total liabilities and
shareholders' equity
$732,643K
Total shareholders'
equity
$665,222K
Total liabilities
$67,421K
Accumulated loss
-$810,831K
Additional paid-in capital
$1,457,238K
Total current
liabilities
$67,421K
Ordinary shares
$14,594K
Accumulated other
comprehensive income
$4,221K
Derivative warrant
liabilities
$50,229K
Accounts payable
$8,090K
Accrued expenses and
other current...
$5,092K
Deferred revenue,
current
$3,987K
Lease liability,
current
$23K
Back
Back
Balance Sheet
source: myfinsight.com
NewAmsterdam Pharma Co N.V. (NAMSW)
NewAmsterdam Pharma Co N.V. (NAMSW)